Teva gets FDA nod for fluvoxamine maleate

Teva Pharmaceuticals (TASE, Nasdaq:TEVA) last week rolled out a fourth United States Food and Drug Administration approval, TheMarker has learned for fluvoxamine maleate.

Fluvoxamine maleate is the generic equivalent of Luvox, developed by Solvay Pharmaceuticals, the U.S. member of the Belgian Solvay group. It is used to treat obsessive compulsive disorder in children and adults.

On Thursday last week Teva said the FDA had approved its ANDA for Nizatidine capsules. Nizatidine is the AB-rated generic equivalent of Eli Lilly's (NYSE:LLY) Axid Pulvules, which is used to treat active duodenal ulcer, and for maintenance therapy of healed duodenal ulcer, GERD and benign gastric ulcer, Teva said.